Graham Craig

I have been reading and lecturing about this for more than a decade: the infliction point on pharma revenues vs investments. Despite the many articles like the one by Ringel: the Eroom’s law, it never seems to happen. Luckily for patients, and luckily also for many thousands of colleagues working in the industry. But now this: « With the exception of the companies making GLP-1 drugs, Foster predicts the industry will continue to see large pharma companies grappling to cut costs through pipeline cuts, layoffs and downsizing facilities. This has already begun, with the likes of Bristol Myers Squibb laying off workers as it restructures and Bayer slashing 3,200 jobs since the beginning of the year. » « The pharma industry is going through volatile shifts — a post-Covid pullback, warnings of a slowdown in US economic growth, tension with China, patent expirations on the horizon and the Inflation Reduction Act — all of which have triggered pharma companies to keep a closer eye on spending.» «  Charles River could be a litmus test of things to come, » What do you think?

23

5 Comments

Illumina has forecasted a 2% to 3% decline in core segment sales for 2024 due to reduced biotech funding impacting R&D investment. Q2 2024 revenue was $1.11 billion, down 5.4% year-over-year but exceeding expectations. Sequencing product sales fell 6.6%, and sequencing instruments dropped 39.9%. Profits were lower than expected, partly due to a $1.47 billion goodwill impairment from the Grail spin-off. Click here to learn more: https://yhoo.it/3AmW6Mw #illumina #genomics #nextgenerationsequencing #venturecapital #privateequity #deerbornedifference

4

Understanding Clostridioides difficile Infections and Antibiotic Stewardship   The decline in HA-CDI in two Montreal hospitals was linked to reduced use of high-risk antibiotics, notably fluoroquinolones. Decreased fluoroquinolone use correlated with significant reductions in both HA-CDI incidence and the proportion of NAP1/027 C difficile strains at one study site. These findings highlight the critical role of antibiotic stewardship in controlling HA-CDI rates and mitigating hypervirulent strains within hospital settings.   https://lnkd.in/eKN7ARdw   Acurx Pharmaceuticals, Inc. (Nasdaq: ACXP) is a publicly held, clinical stage biopharmaceutical company developing a new class of #antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention, and Food and Drug Administration.   #nasdaq #acxp #antibiotics #acurx Acurx Pharmaceuticals, Inc. (Nasdaq: ACXP) David Luci

8

1 Comment